Based on the above-mentioned therapeutic implications of BRCA1/BRCA2 mutation, the most recent update of the National Comprehensive Cancer Network (NCCN) Pancreatic Cancer guideline (v1. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.